

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 18, 2025

FITC anti-human CD56 (NCAM)

RRID:AB_2565964

Type: Antibody

Proper Citation

(BioLegend Cat# 362546, RRID:AB_2565964)

Antibody Information

URL: http://antibodyregistry.org/AB_2565964

Proper Citation: (BioLegend Cat# 362546, RRID:AB_2565964)

Target Antigen: CD56

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD56 (NCAM)

Description: This monoclonal targets CD56

Target Organism: human

Clone ID: Clone 5.1H11

Antibody ID: AB_2565964

Vendor: BioLegend

Catalog Number: 362546

Alternative Catalog Numbers: 362545

Record Creation Time: 20231110T035156+0000

Record Last Update: 20240725T002236+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD56 (NCAM).

No alerts have been found for FITC anti-human CD56 (NCAM).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Li Z, et al. (2024) Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors. STAR protocols, 5(3), 103096.

Shah Z, et al. (2024) Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell stem cell, 31(6), 803.

Li Z, et al. (2024) Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell, 187(3), 624.

Ren X, et al. (2022) Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model. STAR protocols, 3(4), 101818.

Shuwa HA, et al. (2021) Alterations in T and B cell function persist in convalescent COVID-19 patients. Med (New York, N.Y.), 2(6), 720.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell reports. Medicine, 1(8), 100141.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347.